flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney shows greater kidney protection with tirzepatide (#mounjaro) Semaglutide in patients with overweight
Pay in 4 interest-free payments of $5.60 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7




:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)



















